Nova Mentis Life Science Corp C.NOVA

Alternate Symbol(s): NMLSF

Healthcare Biotechnology

Nova Mentis Life Science Corp. is a Canadian biotechnology company. The Company is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. The Company has orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of fragile X syndrome (FXS). Its focus is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and FXS. Its core scientific focus is on chronic neuroinflammatory conditions, which fall under three categories: neurodevelopmental, neurometabolic, and neurodegenerative. The Company operates in one segment, being research and development of psilocybin, and in one geographic area, being Canada, through its wholly owned subsidiaries, Nova Mentis Biotech Corp., and SwabAi Diagnostics Inc.

CSE:NOVA - Post by User

Nova Mentis Life Science Corp

<< Previous

Bullboard Posts

Next >>

Post by Betteryear2on May 04, 2022 8:44am

186 Views

Post# 34654221

Receives Approved Health Canada Importation Permit

Phase 2A Microdose Clinical Study Capsules to be Manufactured

VANCOUVER, BC, May 4, 2022 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce the Company continues to advance its psilocybin-based drug development program following the receipt of a Health Canada approved psilocybin import permit.

https://www.newswire.ca/en/releases/archive/May2022/04/c6025.html